Citigroup
NWBO

Citigroup’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Citigroup’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-43,503
Closed -$64K – 7957
2016
Q1 		$64K Buy
43,503
+24,933
+134% +$49.2K ﹤0.01% 5977
2015
Q4 		$59K Buy
18,570
+14,543
+361% +$69.9K ﹤0.01% 5809
2015
Q3 		$25K Sell
4,027
-161
-4% -$1.5K ﹤0.01% 5897
2015
Q2 		$42K Buy
4,188
+388
+10% +$3.4K ﹤0.01% 5661
2015
Q1 		$28K Sell
3,800
-4,854
-56% -$32.7K ﹤0.01% 5896
2014
Q4 		$46K Buy
8,654
+4,848
+127% +$24.8K ﹤0.01% 5756
2014
Q3 		$19K Buy
3,806
+1,526
+67% +$9.38K ﹤0.01% 5960
2014
Q2 		$15K Sell
2,280
-1,649
-42% -$10.5K ﹤0.01% 5996
2014
Q1 		$28K Sell
3,929
-2,237
-36% -$13.3K ﹤0.01% 5857
2013
Q4 		$23K Buy
+6,166
New +$23.9K ﹤0.01% 6130

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citigroup's NWBO Position: Q2 2016 in Review

Citigroup sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 43,503 shares — an estimated $64K sold.

Citigroup first reported a position in NWBO in Q4 2013 and held it in 10 quarters. The position peaked at $64K in Q1 2016. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

  • Citigroup reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
  • Citigroup sold 43,503 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $64K.
  • Citigroup first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 10 quarters.
  • Citigroup's Northwest Biotherapeutics, Inc. Common stock position peaked at $64K in Q1 2016.
  • 64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Citigroup's 13F filing for Q2 2016, filed 12 Aug 2016.